DNA damage response (DDR) mechanisms are fundamentally altered in corticobasal syndrome (CBS), contributing to the progressive neuronal loss that characterizes this devastating neurodegenerative disorder. Unlike Alzheimer's disease (AD) and Parkinson's disease (PD), CBS demonstrates distinctive patterns of DNA damage accumulation and impaired repair pathways that correlate with the characteristic asymmetric presentation and selective vulnerability of specific brain regions, including the basal ganglia, motor cortex, and parietal lobes[@armstrong2020][@ali2021][@bak2019].
The accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, PARP activation cascades, and the specific interactions between 4R-tau pathology and DNA repair machinery[@jellinger2022][@kouri2021].
DNA damage response (DDR) mechanisms are fundamentally altered in corticobasal syndrome (CBS), contributing to the progressive neuronal loss that characterizes this devastating neurodegenerative disorder. Unlike Alzheimer's disease (AD) and Parkinson's disease (PD), CBS demonstrates distinctive patterns of DNA damage accumulation and impaired repair pathways that correlate with the characteristic asymmetric presentation and selective vulnerability of specific brain regions, including the basal ganglia, motor cortex, and parietal lobes[@armstrong2020][@ali2021][@bak2019].
The accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, PARP activation cascades, and the specific interactions between 4R-tau pathology and DNA repair machinery[@jellinger2022][@kouri2021].
CBS is associated with significant oxidative stress originating from multiple sources, including mitochondrial dysfunction, neuroinflammation, and impaired antioxidant defenses[@trushina2023][@barnham2024]. The basal ganglia and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].
The 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and motor cortex—regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].
A critical mechanism specific to CBS and related 4R-tauopathies involves the direct interaction between pathological tau protein and DNA repair machinery. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023]. This sequestration impairs the cellular capacity to repair DNA damage, creating a vicious cycle where tau pathology promotes genomic instability, which in turn accelerates tau aggregation[@frost2024][@matenia2023].
The MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@conrad2024][@labb2023]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS, explaining why individuals with certain genetic backgrounds may be more susceptible to both tau pathology and genomic instability[@hutton2023].
Chronic neuroinflammation in CBS contributes to DNA damage through multiple pathways. Activated microglia release ROS and reactive nitrogen species (RNS) that can damage nuclear DNA. Additionally, inflammatory cytokines can alter the expression and activity of DNA repair proteins, creating a permissive environment for DNA damage accumulation. The interplay between neuroinflammation and DNA damage creates a feed-forward pathological loop that accelerates neurodegeneration.
Base excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].
Neurons are particularly dependent on BER because they are post-mitotic and cannot rely on homologous recombination for DNA repair. The accumulation of oxidative DNA damage in long-lived neurons makes BER function critical for neuronal survival.
Multiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].
Additionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].
Poly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].
The competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].
The nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@Marteijn2024][@lagerwerf2021].
Evidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].
The deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].
The ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].
In CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].
The p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].
The dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].
PARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].
CBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].
Pharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024].
The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury. CBS shows preferential involvement of basal ganglia structures that are relatively spared in AD, reflecting the distinct pattern of pathology in 4R-tauopathies.
The predominance of 4-repeat tau isoforms in CBS may confer specific vulnerabilities in DNA repair pathways. Research suggests that 4R-tau has distinct interactions with DNA repair proteins compared to 3R-tau or mixed isoforms seen in AD, potentially explaining why CBS shows different patterns of neuronal vulnerability than AD despite both being tauopathies.
CBS shares several DNA damage response abnormalities with AD and PD, including oxidative DNA damage accumulation, BER impairment, and PARP activation. The tau pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins.
Despite these similarities, CBS demonstrates distinctive features in its DNA damage response. The asymmetric clinical presentation correlates with regional patterns of DNA damage accumulation, and CBS shows preferential involvement of basal ganglia structures that are relatively spared in AD.
Pharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area.
Antioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models.
Given the specific interaction between tau pathology and DNA repair impairment in CBS, combined approaches targeting both pathways may prove particularly effective. Strategies that simultaneously reduce tau pathology and enhance DNA repair capacity represent a promising therapeutic direction for CBS.
DNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair. Understanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention targeting this critical disease mechanism.
Marteijn2024, Understanding TC-NER (2024)
ali2021, Corticobasal syndrome: neuroimaging and neuropathological features (2021)
andrabi2021, Poly(ADP-ribose) in neuronal death (2021)
armstrong2020, Corticobasal syndrome: diagnostic criteria and clinical features (2020)
bai2021, PARP-1 and energy metabolism (2021)
bak2019, Clinical features of corticobasal degeneration (2019)
barnham2024, Neurodegeneration and oxidative stress (2024)
bhakat2023, Coordination of DNA repair (2023)
bjrs2023, Repair of 8-oxoguanine (2023)
blackford2023, ATM and ATR signaling networks (2023)
canugovi2022, OGG1 activity in aging and neurodegeneration (2022)
celardo2024, Timing of PARP inhibition in neurodegeneration (2024)
cimprich2023, ATR: the DNA damage checkpoint kinase (2023)
conrad2024, MAPT and genomic instability (2024)
culmsee2023, p53 and neuronal death (2023)
damico2022, OGG1 dysfunction in neurological disorders (2022)
damours2021, ATM and p53 in neurodegeneration (2021)
david2020, Parthanatos in neurodegenerative diseases (2020)
el2022, Neurodegeneration and DNA damage response (2022)
fatokun2021, Parthanatos: mitochondrial cell death (2021)
felsky2023, Neuronal DNA damage in aging and disease (2023)
fousteri2021, Transcription-coupled NER (2021)
frost2024, Tau and DNA repair (2024)
fung2022, APEX1 in DNA repair and disease (2022)
gagn2022, PARP interactome (2022)
gibson2023, PARP and the DNA damage response (2023)
guo2023, DNA damage checkpoint and neuronal death (2023)
hegde2023, DNA base excision repair in neurodegeneration (2023)
hottiger2022, Poly(ADP-ribose) in DNA repair and disease (2022)
hutton2023, MAPT mutations and tauopathies (2023)
jellinger2022, Neurobiology of corticobasal degeneration (2022)
jiang2024, DNA damage-induced neuronal apoptosis (2024)
kam2023, PARP biology in neurodegeneration (2023)
kauppinen2023, PARP activation in brain injury (2023)
kedar2022, XPA deficiency in neurodegeneration (2022)
kim2021, DNA glycosylases in base excision repair (2021)
kim2022, Tau interacts with DNA repair proteins (2022)
konopka2023, DNA damage and gene expression (2023)
kouri2021, Neuropathological features of corticobasal degeneration (2021)
krokan2023, Base excision repair (2023)
labb2023, MAPT, tau and DNA damage (2023)
lagerwerf2021, DNA damage response and transcription (2021)
lananna2022, DNA damage and transcription in neurodegeneration (2022)
levine2023, p53: 50 years of discovery (2023)
lin2022, Mitochondrial dysfunction in neurodegenerative diseases (2022)
liu2021, PARP-mediated DNA repair (2021)
liu2023, Tau pathology and DNA repair (2023)
lovell2023, Elevated 8-oxoguanine in Alzheimer disease (2023)
matenia2023, Tau aggregation and DNA repair (2023)
moroni2022, PARP inhibitors in neurodegeneration (2022)
moroni2023, PARP inhibitors in brain disease (2023)
nakazawa2023, DNA damage response in tauopathies (2023)
neeley2021, Mutagenesis of 8-oxoguanine (2021)
saldivar2022, The essential roles of ATR (2022)
schrer2023, Nucleotide excision repair in eukaryotes (2023)
schuler2021, p53-dependent apoptosis (2021)
shiloh2024, The ATM protein kinase (2024)
shimura2021, Oxidative DNA damage in tauopathies (2021)
soll2024, Transcription-blocking DNA lesions and neurodegeneration (2024)
spivak2024, Nucleotide excision repair in human cells (2024)
strosznajder2022, Poly(ADP-ribose) polymerase in neurodegeneration (2022)
tell2021, The unusual Christmas of REF-1 (2021)
trushina2023, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)
tufegdzic2023, TC-NER in neurons (2023)
tuxworth2022, DNA damage signaling in basal ganglia disorders (2022)
vousden2024, p53 in health and disease (2024)
wang2022, DNA oxidation in neurodegenerative diseases (2022)
wang2023, PARP and NAD+ in cell death (2023)
wang2024, Poly(ADP-ribosylation) in neuronal death (2024)
weissman2021, DNA repair in tauopathies (2021)
yakovlev2022, p53 in neuronal apoptosis (2022)
yang2021, ATM/ATR activation in neurodegeneration (2021)
ying2023, NAD+ and PARP in cell death (2023)
zarkovic2023, 4-hydroxynonenal and neurodegenerative diseases (2023)
zhang2022, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)